Zhang JT, Zhang N, Dong XT, Wang XR, Ma HW, Liu YD, Li MR. Efficacy and safety of fecal microbiota transplantation for treatment of ulcerative colitis: A post-consensus systematic review and meta-analysis. World J Clin Cases 2024; 12(21): 4691-4702 [PMID: 39070844 DOI: 10.12998/wjcc.v12.i21.4691]
Corresponding Author of This Article
Mu-Ran Li, MD, Chief Doctor, Department of Gastroenterology, Tianjin Union Medical Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300122, China. muranli@126.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Jul 26, 2024; 12(21): 4691-4702 Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4691
Efficacy and safety of fecal microbiota transplantation for treatment of ulcerative colitis: A post-consensus systematic review and meta-analysis
Jin-Tao Zhang, Nan Zhang, Xue-Tao Dong, Xiao-Ran Wang, Hong-Wen Ma, Yan-Di Liu, Mu-Ran Li
Jin-Tao Zhang, Department of Clinical Medicine, School of Medicine, Nankai University, Tianjin 300071, China
Nan Zhang, Xue-Tao Dong, Xiao-Ran Wang, Hong-Wen Ma, Yan-Di Liu, Mu-Ran Li, Department of Gastroenterology, Tianjin Union Medical Center, Tianjin 300122, China
Author contributions: Li MR outlining and coordinating the work of co-authors; Zhang JT and Zhang N performed the research and analyzed the data; Zhang JT, Zhang N, Dong XT, Wang XR, Ma HW and Liu YD wrote and edit the manuscript; All authors have read and agreed to the published version of the manuscript.
Supported bythe Tianjin Health Science and Technology Project, No. TJWJ2021MS011.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mu-Ran Li, MD, Chief Doctor, Department of Gastroenterology, Tianjin Union Medical Center, No. 190 Jieyuan Road, Hongqiao District, Tianjin 300122, China. muranli@126.com
Received: March 27, 2024 Revised: May 28, 2024 Accepted: June 19, 2024 Published online: July 26, 2024 Processing time: 95 Days and 22.9 Hours
Abstract
BACKGROUND
Numerous studies have assessed the efficacy and safety of fecal microbiota transplantation (FMT) as a therapy for ulcerative colitis (UC). However, the treatment processes and outcomes of these studies vary.
AIM
To evaluate the efficacy and safety of FMT for treating UC by conducting a systematic meta-analysis.
METHODS
The inclusion criteria involved reports of adult patients with UC treated with FMT, while studies that did not report clinical outcomes or that included patients with infection were excluded. Clinical remission (CR) and endoscopic remission (ER) were the primary and secondary outcomes, respectively.
RESULTS
We included nine studies retrieved from five electronic databases. The FMT group had better CR than the control group [relative risk (RR) = 1.53; 95% confidence interval (CI): 1.19-1.94; P < 0.0008]. ER was statistically significantly different between the two groups (RR = 2.80; 95%CI: 1.93-4.05; P < 0.00001). Adverse events did not differ significantly between the two groups.
CONCLUSION
FMT demonstrates favorable performance and safety; however, well-designed randomized clinical trials are still needed before the widespread use of FMT can be recommended. Furthermore, standardizing the FMT process is urgently needed for improved safety and efficacy.
Core Tip: We conducted a meta-analysis on the use of fecal microbiota transplantation (FMT) for treating ulcerative colitis (UC), marking the first meta-analysis following the Rome consensus by experts in inflammatory bowel disease. This study stands out as it contributes to the establishment of standard procedures for FMT in UC treatment and facilitates its clinical application. Through a comprehensive analysis of existing research data, we found that FMT holds significant potential in UC treatment and has shown promising efficacy to a certain extent. This finding provides robust support for expanding clinical practices while also suggesting further avenues for research to elucidate the mechanisms and optimal therapeutic strategies of FMT in UC treatment.
